Aeterna Zentaris to Present at the Q2 Virtual Investor Summit

Rhea-AI Summary

Aeterna Zentaris Inc. (NASDAQ: AEZS) announced that CEO Dr. Klaus Paulini will present at the Q2 Virtual Investor Summit on May 17, 2021 at 8:45 AM ET. The event will include a live video webcast accessible on the Company's website. Management will also hold one-on-one virtual meetings with registered investors. Aeterna is a biopharmaceutical company focused on unmet medical needs, with its lead product macimorelin, the only approved oral test for adult growth hormone deficiency. The company is advancing a pipeline addressing various conditions.

– Live video webcast with CEO, Dr. Klaus Paulini, on Monday, May 17, 2021 at 8:45 AM ET

CHARLESTON, S.C., May 10, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna, will present at the Q2 Virtual Investor Summit on Monday, May 17^th at 8:45 AM ET.

In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference website.

A live video webcast of the presentation will be accessible on the Events page in the Investors section of the Company’s website (www.zentaris.com), and will be archived for 90 days following the event.

About Aeterna Zentaris Inc.

Aeterna Zentaris is a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin, is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD) in collaboration with Novo Nordisk.

Aeterna Zentaris is dedicated to the development of therapeutic assets and has recently taken steps to establish a growing pipeline to address unmet medical needs across a number of indications, including neuromyelitis optica spectrum disorder (NMOSD), hypoparathyroidism and an undisclosed neurodegenerative disease. Additionally, the Company is developing an oral prophylactic bacterial vaccine against SARS-CoV-2, the virus that causes COVID-19.

For more information, please visit www.zentaris.com and connect with the Company on Twitter, LinkedIn and Facebook.

Investor Contact:

Jenene Thomas
JTC Team
T (US): +1 (833) 475-8247
E: aezs@jtcir.com

FAQ

What is Aeterna Zentaris's presentation date at the Q2 Virtual Investor Summit?

Aeterna Zentaris's CEO, Dr. Klaus Paulini, will present on May 17, 2021, at 8:45 AM ET.

Where can I watch Aeterna Zentaris's live presentation?

The live video webcast of Aeterna Zentaris's presentation will be available on their official website.

What is macimorelin developed by Aeterna Zentaris?

Macimorelin is the first approved oral test for diagnosing adult growth hormone deficiency.

What conditions is Aeterna Zentaris targeting with its pipeline?

Aeterna Zentaris is developing treatments for conditions like neuromyelitis optica spectrum disorder, hypoparathyroidism, and an undisclosed neurodegenerative disease.

How can I participate in one-on-one meetings with Aeterna Zentaris's management?

Qualified members of the investor community can register for the Q2 Virtual Investor Summit to participate in one-on-one meetings.